Epidermal growth factor receptor tyrosine kinase inhibitor–resistant disease
Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …
we present an update on new controversies and conclusions regarding the disease …
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
JF Gainor, AT Shaw - Journal of clinical oncology, 2013 - ascopubs.org
The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
HA Yu, ME Arcila, N Rekhtman, CS Sima… - Clinical cancer …, 2013 - AACR
Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …
[HTML][HTML] Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
GR Oxnard, PC Lo, M Nishino, SE Dahlberg… - Journal of Thoracic …, 2013 - Elsevier
Introduction Exon 20 insertions are the third most common family of epidermal growth factor
receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known …
receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known …
[HTML][HTML] Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed …
AY Helena, CS Sima, J Huang, SB Solomon… - Journal of Thoracic …, 2013 - Elsevier
Background Development of acquired resistance limits the utility of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …
[HTML][HTML] A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
KE Ware, TK Hinz, E Kleczko, KR Singleton, LA Marek… - Oncogenesis, 2013 - nature.com
Despite initial and often dramatic responses of epidermal growth factor receptor (EGFR)-
addicted lung tumors to the EGFR-specific tyrosine kinase inhibitors (TKIs), gefitinib and …
addicted lung tumors to the EGFR-specific tyrosine kinase inhibitors (TKIs), gefitinib and …
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
JJ Yang, HJ Chen, HH Yan, XC Zhang, Q Zhou, J Su… - Lung cancer, 2013 - Elsevier
BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
AB Cortot, CE Repellin, T Shimamura, M Capelletti… - Cancer research, 2013 - AACR
The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited
by the development of drug resistance. The most common mechanism of drug resistance is …
by the development of drug resistance. The most common mechanism of drug resistance is …
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Cancer, 2013 - Wiley Online Library
BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
MA Davare, A Saborowski, CA Eide… - Proceedings of the …, 2013 - National Acad Sciences
The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the
malignant transformation of multiple cancers, including lung adenocarcinoma …
malignant transformation of multiple cancers, including lung adenocarcinoma …